GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Agile Therapeutics Inc (OTCPK:AGRX) » Definitions » Change In Inventory

Agile Therapeutics (Agile Therapeutics) Change In Inventory : $-2.34 Mil (TTM As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Agile Therapeutics Change In Inventory?

Agile Therapeutics's change in inventory for the quarter that ended in Mar. 2024 was $-1.01 Mil. It means Agile Therapeutics's inventory increased by $1.01 Mil from Dec. 2023 to Mar. 2024 .

Agile Therapeutics's change in inventory for the fiscal year that ended in Dec. 2023 was $-2.21 Mil. It means Agile Therapeutics's inventory increased by $2.21 Mil from Dec. 2022 to Dec. 2023 .

Agile Therapeutics's Total Inventories for the quarter that ended in Mar. 2024 was $3.75 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Agile Therapeutics's Days Inventory for the quarter that ended in Mar. 2024 was 176.15.

Inventory Turnover measures how fast the company turns over its inventory within a year. Agile Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.52.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Agile Therapeutics's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.57.

Agile Therapeutics Change In Inventory Historical Data

The historical data trend for Agile Therapeutics's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agile Therapeutics Change In Inventory Chart

Agile Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Inventory
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -6.29 -0.76 -2.21

Agile Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Change In Inventory Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.88 -0.33 0.13 -1.13 -1.01

Agile Therapeutics Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.34 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Agile Therapeutics  (OTCPK:AGRX) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Agile Therapeutics's Days Inventory for the quarter that ended in is calculated as:

Days Inventory=Average Total Inventories/Cost of Goods Sold*Days in Period
=3.243/1.68*365 / 4
=176.15

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Agile Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover=Cost of Goods Sold / Average Total Inventories
=1.68 / 3.243
=0.52

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Agile Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue=Average Total Inventories / Revenue
=3.243 / 5.716
=0.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Agile Therapeutics Change In Inventory Related Terms

Thank you for viewing the detailed overview of Agile Therapeutics's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Agile Therapeutics (Agile Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Agile Therapeutics Inc (OTCPK:AGRX) » Definitions » Change In Inventory
Comparable Companies
PRFX JUVAF CLVR STEK OWPC KOAN EVOK UPC PTPI CNNC ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
N/A
Address
500 College Road East, Suite 310, Princeton, NJ, USA, 08540
Website
https://www.agiletherapeutics.com
Agile Therapeutics Inc is a women's healthcare company to fulfill the unmet health needs of women. Its product candidates are designed to provide women with contraceptive options. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. The Company views its operations and manages its business in one operating and reporting segment, which is the business of commercializing its transdermal patch for use in contraception.
Executives
Scott M Coiante officer: Chief Financial Officer 101 POOR FARM ROAD 3RD FLOOR, PRINCETON NJ 08540
Josephine Torrente director 101 POOR FARM ROAD, PRINCETON NY 08540
Sandra Carson director C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540
John W Hubbard director 101 POOR FARM ROAD 3RD FLOOR, PRINCETON NJ 08540
Fischer Seth H.z. director C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Sharon Surrey Barbari director 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Amy Welsh officer: Chief Commercial Officer 500 COLLEGE ROAD EAST, SUITE 310, C/O AGILE THERAPEUTICS, INC., PRINCETON NJ 08540
Alfred Altomari director, officer: Chief Executive Officer C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Dennis Reilly officer: Chief Financial Officer 600 COLLEGE ROAD EAST, PRINCETON NJ 08540
Jason Butch officer: Principal Accounting Officer 101 POOR FARM ROAD, PRINCETON NJ 08540
Paul Korner officer: Sr. VP & Chief Medical Officer C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 200, FREMONT CA 94555
Abhijeet J Lele director, See remarks C/O EP MEDYSTEMS, 575 RTE 73 N, WEST BERLIN NJ 08091
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003